Northwestern University Feinberg School of Medicine

Northwestern University Feinberg School of Medicine

Research & Clinical Trials

Join A Research Study

Alzheimer’s Disease Core Center Study
Download PDF flyer of this study
STATUS: ENROLLING
The Northwestern Alzheimer’s Disease Center (NADC) was established with funding from the National Institute on Aging (NIA) in 1996.  The primary goals of the center are to 1) provide state-of-the-art care to patients with Alzheimer’s disease and related disorders, and 2) support clinical and basic research on memory and aging through the collection and storage of clinical data and brain tissue from research participants.   Clinical data and tissue are distributed to collaborators throughout Northwestern, as well as to other Alzheimer Disease Centers. The NADC is comprised of five Cores: Clinical, Administrative, Neuropathology, Data Management and Biostatistics, and Education. Over the past year, the Clinical and Data cores have worked closely with the Education and Neuropathology cores to recruit and enroll subjects, facilitate brain donations, support investigations of dementia and aging, and educate the public on effectively coping with these illnesses. 

Language in Primary Progressive Aphasia Study
Download PDF flyer of this study
STATUS: ENROLLING
The The PPA study will allow the CNADC a more in-depth look at specific language, neuropsychological, and neurological issues that arise as PPA disorder progresses. This three day-long research study investigates a variety of topics, primarily relating to language. The information obtained from all participants could lead to exciting developments in the knowledge and treatment of PPA. We are currently seeking persons with PPA to enroll as participants in the study. All participants will be compensated for their participation. If you are interested in becoming a participant or would like more information about this study, please contact: Christina Wieneke, c-wieneke@northwestern.edu or Phone: 312-908-9681

Northwestern University SuperAging™ Study
Download PDF flyer of this study
STATUS: ENROLLING
We are currently conducting a longitudinal research study to determine what factors help keep older individuals highly functional and free of cognitive decline as they progress through the aging process. The study consists of three visits over the course of 3 years. Participants must be over 80. If you are interested, please contact Dr. Emily Rogalski, at 312-503-2716.

Study of Nasal Insulin to Fight Forgetfulness (SNIFF)
Download PDF flyer of this study
STATUS: RECRUITING
The SNIFF study will evaluate whether a type of insulin improves memory when administered through the nose as a nasal spray to adults with amnestic Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD). The study will also look at the effect of insulin on brain structure and function, cerebrospinal fluid (CSF) biomarkers and blood biomarkers.

Participants will be given a nasal spray device with either insulin or placebo. Participants will be randomly assigned to the treatment or the placebo group for 12 months followed by six months in which all participants will receive insulin. During the first 12 months neither study participants nor study staff will know who is receiving active treatment and who is receiving placebo (called a "double-blind" study). Individuals between 55 and 85 years of age with a diagnosis of amnestic mild cognitive impairment (MCI) or early AD can be considered.

ADNI2
Download PDF flyer of this study
STATUS: ACTIVE, CLOSED TO ENROLLMENT
The Alzheimer's Disease Neuroimaging Initiative - 2 (ADNI2) study is a newly funded NIA study that builds upon the previous ADNI1 and ADNI-GO studies. This study will continue to follow ADNI-GO and ADNI1 subjects longitudinally for an additional 5 years. In addition, ADNI2 will recruit new subjects from one of four groups of individuals: cognitively normal (CN), eMCI (early mild cognitive impairment), IMCI (late mild cognitive impairment), and mild-AD. This study aims to follow all subjects except for the mild-AD subjects (mild AD subject participation will end at 24 months) for up to 54 months by employing body fluid (blood, urine, CSF), neuropsychological testing, braing MRIs and PET scans at different time points throughout the subject's participation.  ADNI2 is a non randomized longitudinal study that offers no drug or investigational treatment.

Volunteer 

Participants May Receive 

  • Participants receive annual evaluations of memory and other cognitive functions
  • We will provide participants with information on the latest treatments and preventions of memory loss
  • Participants will also receive our quarterly newsletter and other educational materials relevant to preserving memory health
  • Social work advice is available to inform participants about community resources
  • No cost for participation

Initial Research Visits Include

The enrollment visit takes approximately 2 hours. During this time:

  • Demographic information and medical history is gathered from participants and their family members
  • Paper and pencil tests are given to evaluate memory and thinking skills
  • A social worker meets with family members
  • A blood sample is taken to test for  genetic markers
  • Participants are informed of our brain donation program

Annual Return Visits Include

The annual return visits take approximately 90 minutes. During this time:

  • Information about the previous year is gathered from participants and their family members
  • Paper and pencil tests are given to evaluate memory and thinking skills

This page last updated Dec 20, 2013

Cognitive Neurology and Alzheimer's Disease Center
320 E Superior, Searle 11
Chicago, IL 60611
Phone: 312-908-9339
Fax: 312-908-8789
Email Us

Contact Northwestern University |  Disclaimer |  Campus Emergency Information |  Policy Statements

Northwestern Home  |  Northwestern Calendar: Plan-It Purple  |  Northwestern Search